Methods for detecting teratogenic agents in man. by Shepard, T H & Miller, J R
Environmental Health Perspectives
Vol. 13, pp. 141-146, 1976
Methods for Detecting Teratogenic
Agents in Man*
by Thomas H. Shepardt and James R. Millert
At a multidiscipline international meeting sponsored by L'Institut de la Vie held at
Guadeloupe in January 1974, current methods for detecting teratogenic agents were out-
lined and discussed. Recommendations of the participants of the conference wete: recog-
nize the limitations ofthe present defenses against teratogenic agents; educate the public
and medical profession about the known human teratogenic agents; select for animal
teratogenicity screening among new and existing agents by emphasizing substances to
which the entire population will be exposed, agents to which pregnant women are exposed,
viruses which are found to persist in the human fetus, and agents which have become
suspect from clinical experience; recognize that nearly all compounds have a fetotoxic
dose but that this does not imply teratogenicity; encourage the development of new, quick
in vitro testing methods for detecting teratogenic agents; monitor for sudden increases in
the frequency of specific malformations in newborn infants and in aborted fetuses; assure
that expert multidiscipline committees are available to evaluate the threat when suspected
teratogens are reported; improve teratology information storage and retrieval systems by
record linkage of clinical data, linkage between computer systems, and universal iden-
tifier system for chemical compounds and congenical malformations; foster the exchange
of data, particularly those held by the pharmaceutical industry.
Introduction
The question "Can we prevent another
thalidomide disaster?" would have to be answered
in the negative today, 14 years after the fact.
Although recurrence today is much less likely, the
possibility may never beeliminated. The purposes of
the present paper are to outline and discuss our
current methods for detecting teratogenic agents
and to make some wide-based proposals for imple-
menting new approaches to the problem.
A teratogenic agent is a drug, chemical, virus, or
physical agent which by acting during the
embryonic or fetal period alters morphology or sub-
sequent function in the post natal period. Although
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over 600 ofthese agents have been cataloged in the
experimental animal, hardly more than 20 of this
group are known (1-4) to be active in man (Table
1).
Errors of intrauterine development are esti-
mated to produce a prenatal loss in the human in
excess of 40%. Serious defects can be detected in
about 3% of newborn babies, and the number
detected gradually rises to about 8% during the
following 10 years. Professor Maurice Marois,
Director of l'Institut de la Vie, has recognized the
impact ofthis problem on the quality ofhuman life
and has initiated efforts toward evaluating the cur-
rent status ofour teratologic defenses and integrat-
ing and improving our emerging and existing
methods. This was translated into a multidiscipline
international meeting held on the island of
Guadeloupe in January of 1974. The participants
ofthis conference believed at the close ofthe meet-
ing that some important understandings and con-
clusions had been reached and that these should be
recorded in a form that would be accessible to in-
terested scientists in universities, governments, and
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Radiation
Therapeutic
Radioiodine
Atomic weapons
Infections
Rubella virus
Cytomegalovirus
Herpes virus hominis I and ?II
Toxoplasmosis
Syphilis
?Varicella virus
Venezuelan equine encephalitis virus
Maternal metabolic imbalance
Endemic cretinism
?Diabetes
Phenylketonuria
Virulizing tumors
Alcoholism
Drugs and environmental chemicals
Androgenic hormones
Aminopterin and methylaminopterin
Cyclophosphamide
Busulfan
Thalidomide
Mercury
Chlorobiphenyls
Diethylstilbestrol
Diphenylhydantoin
Coumarin derivatives
DEFENSE m
LATE MONITORING
EARLY MONITORING
NsAEI
FIGURE 1. Perspective of our major defenses against
teratogenic agents. The first defense is standard testing
carried out in pregnant animals. A limited knowledge of
the biologic activity of chemical structure contributes.
The second wall, which should be in close association
with the first, consists of in vitro testing by tissue and
organ cultures as well as studies of ova and whole
embryo explants. Defense II, or early monitoring offetus
and newborn, is necessary because the first defenses still
are inadequate. Late monitoring is illustrated by the ap-
pearance ofvaginal carcinomas in young women exposed
in utero to diethylstilbestrol (6). This later defense is
manned by the alert medical practitioner. Figure
reproduced with permission from Shepard (2).
industries. In recording the consensus of our
deliberations on such a very wide ranging subject,
we are bound to strike some point of disagreement
in the mind ofevery discerning reader. A more com-
plete report of the proceedings including discus-
sions, appears elsewhere (5).
It is possible to conceptualize existing defenses
as three walls or hurdles (Fig. 1). In addition to ex-
isting potential teratogenic agents, an estimated
2000 new chemicals are introduced into the en-
vironment each year. The standard teratogenicity
testing of chemicals in pregnant laboratory
animals would represent the first defense wall.
This defense, erected only after the devastating
effects of thalidomide, is held by a few to be effec-
tive, but a majority of scientists recognize that it
has severe limitations. The use of chemical struc-
ture as a predictor ofteratogenicity is theoretically
ofgreat promise but to date has seen little practical
application. A number of new tests based on in
vitro techniques are available but are relatively lit-
tle used at present. The utility of these methods,
which include tissue and organ culture, ova
culture, and whole embryo culture, will be dis-
cussed at some length below. A second defense (or
more properly a watchtower) consists of monitor-
ing and is necessary because ofthe admitted inade-
quacy of the first defense. Monitoring may be car-
ried out on embryonic and fetal loss, fluid obtained
from the amniotic cavity, or on the newborn. A
third defense, which is only beginning to be used, is
that of late monitoring, an example ofwhich might
be the demonstration that women who were ex-
posed to diethylstilbestrol during the firsttrimester
of fetal life are at increased risk for vaginal cancer
(6).
Animal Testing and Pharmacologic
Prediction
Unfortunately, the narrow view of teratology
often includes only the administration of various
drugs and chemicals to small laboratory animals.
Although this area is a substantial and legitimate
area of teratology, it is clear that teratologists in-
clude a verywide spectrum ofscientists encompass-
ing many endeavors from cell biology to human
epidemiology.
What priorities should guide us in a choice of
agents to be tested in pregnant laboratory animals?
Substances to which the entire population will be
exposed should receive priority. Examples of this
are the food additives (GRAS list, generally
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scrutiny by the Federal Drug Agency, and com-
pounds such as nitrilotriacetic acid (7). Nitrilo-
triacetic acid, a biodegradeable substitute for
phosphates in detergents, ifwidelymarketed, might
be ingested by humans at a level of around 100
,ug/day. A second category ofagents to be tested are
those to which pregnant women may be exposed.
Some substances might inadvertently be ingested
by a pregnant woman, and others such as anti-
biotics and diuretics may be necessary therapeutic
agents. A third category are the virologic agents. If
it can be shown that a virus resides in the embryo-
fetus, careful and long-term testing is indicated. In-
advertentin utero exposure to livevaccines orvirus
diseases before therapeutic or spontaneous abor-
tion should merit virologic culture of conception
products on an ongoing basis. Finally, any agent
which becomes suspect from clinical observations
certainly deserves immediate attention.
The question of the species to be used and the
number of test animals was discussed. Some par-
ticipants recommended thetesting ofa mongrelized
or genetically heterogeneous groups of animals in
order to identify any genetic subgroup which might
be highly susceptible to a teratogenic agent.
Although this is an important goal, the field of
pharmacogenetics is probably not sufficiently tech-
nically developed to make this feasible in the near
future. The use of subhuman primates should
probably be reserved for special situations where
an agent must be used during human pregnancy or
where there is clinical reason to suspect human
teratogenicity.
The dosage ofthe test substance should be max-
imal but should not interfere appreciably with the
health of the maternal animal. Practically any
substance in high enough dosage can be shown to
be fetotoxic. Wilson and many others recommend
that a fetotoxic response should be obtained when
testing substances. The general acceptance by
regulatory agents that compounds do have a
fetotoxic dose should help to prevent us from ex-
cluding the many therapeutic agents which are un-
necessarily discarded because offetotoxic effects at
high dose. We agree with the report by the Cana-
dian Ministry of Health and Welfare (8) that high
dose pulses ofthetestsubstance should begiven for
relatively short periods during organogenesis. This
tends to decrease maternal adaption to prolonged
exposure which might lead to reduced levels reach-
ing the fetus. Because ofthe findings that the fetus
may be more susceptible to carcinogens than the
postnatal animal (9), more emphasis should be
placed on the appearance of tumors in animals
tested over several generations.
At some point in the future our knowledge of
pharmacologic action ofchemicals should allow us
to predict accurately the biologic activity of new
substances. This field of endeavor should be en-
couraged in every way, but at the present time it
offers little aid in preventing human teratogenicity.
In Vitro Testing
Many participants of the conference accepted
the idea thatin vitro testing should play a more im-
portant role in our defenses against teratogenic
agents. However, it was also accepted that routine
screening by most ofthese methods would be oflit-
tle help and would certainly not displace the use of
pregnant animal testing. The use of the in vitro
tests is of a special importance for elucidating
mechanisms of teratogenesis. With better under-
standing of the mechanisms, more intelligent
measures can be directed toward interruption of
human embryopathy. A number of investigators
recommended that human material, particularly
that received during therapeutic abortion, be used
for tissue in organ culture testing of teratogenic
agents. This material should be utilized bydevelop-
mental biologists after careful peer review, and
with fully informed consent of the donors.
Human Monitoring
The 3% of neonates with congenital defects
represent only the tip of a larger iceberg of
embryonic and fetal loss. We can learn a great deal
by studying the larger part of this iceberg. One
might expect that prenatal losses would be a more
dramatic and sensitive index of the response to a
teratogenic agent. By study ofembryos and fetuses
from spontaneous abortions in the first trimester,
an earlier warning might be established which
could provide epidemiologic information some 6
months before a teratogenic effect would be
detected in newborns. Another advantage to this
early monitoring is a shortening ofthe period from
the time of teratogenic exposure to the time of in-
quiry ofthe mother. This could be less than a week
as compared to the 7-8 month interval when the
history is taken from the mother of a neonate.
Systematic monitoring of human embryonic and
fetal loss should be introduced.
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in many countries. These would probably fail to
detect minor changes in brain function or longterm
carcinogenesis. Generally only very easily recog-
nized physical defects are recorded; the larger por-
tion of congenital disease identified after the
newborn period (60% ) is usually not included.
Although these systems involve many variations
due to artifacts associated with data collection, a
continuous recording by time and place, and regis-
try of congenital defects should provide an impor-
tant warning of teratogenic action by new chemi-
cal, physical or infectious agents. The neonate data
maybe used to testhypotheses, as illustrated bythe
initial report from Australia (10) that a tricyclic
antidepressant (Imiprimine) might be the cause of
limb reduction defects. Using their own case data,
the monitoring groups in Atlanta and Canada were
able to make a rapid, detailed survey of all women
having given birth to children with limb defects.
Their negative results (11, 12) in hundreds of
women offered strong evidence that this drug was
not a highly potent human teratogen.
Another concept of importance is that of record
linkage (birth, death, hospital, pharmacy, and
school records). Some of the epidemiologic infor-
mation required may involve two- or three-genera-
tion studies. This factor tends to exclude observa-
tion by one observer, but computerized methods for
linking records can overcome this problem to some
degree. With the present day computer systems it
should be possible to link birth records ofchildren
with malformations to drug prescriptions given the
mother, previous disease, and ill health of the
parent and other affected members. A recent
publication from the Kaiser Permanente System
(13) reports the use of record linkage to study the
association between prescriptions filled for women
and serious congenital defects in their offspring. A
fourfold increase in defect rate was found when the
mothers took the commonly used tranquilizers,
meprobamate and chlordiazepoxide during the
first 42 days of gestation. The rate was not
similarly increased in a group taking barbiturates.
Significantly, all the prescriptions were written by
physicians not involved in caring forthe pregnancy.
Those concerned with the organization of health
care systems should be aware of the need for
designing methods of record keeping in a form
suitable for record linkage.
Regulatory agencies should set up standard
bodies of experts to investigate any suspected
teratogens. These groups should consist ofpediatri-
cians, obstetricians, epidemiologists, and other ap-
propriate consultants. In general, the observers
reporting the suspected teratogen should not be
responsible for organizing or conducting the full in-
vestigation.
Many teratologists assume that a large variety
of congenital defects result from several develop-
ment-controlling genes acting in concert with en-
vironmental agents. Fraser and his students have
illustrated this mechanism in certain inbred strains
of mice (A/J) and are beginning to make practical
human applicationsto the control ofcertain defects
(14, 15). The A/J mouse exhibits a higher natural
incidence of cleft lip and palate than certain other
strains, and this is related to differences in the
topographic relations of the embryonic facial pro-
cesses (16). Other controlling genes for the develop-
ment ofthe palate are known to predisposeto clefts
(14). Examples such as shortening of the head,
changes in mandibular length, or mechanisms that
by causing tongue obstruction might prevent nor-
mal palatal shelf closure have been studied by
using mutant genes or inbred animal models. Most
of the environmental agents (aspirin, cortisone)
known to produce clefts in animals are more effec-
tive in these inbred strains. It seems imperative to
accelerate the application of these principles to
man. This requires quantitative methods for iden-
tifying the susceptible human genotypes (the A/J
man?) and the environmental agents that might
contribute to the multifactorially caused defects.
Since the modification of gene action may be tech-
nically impossible for some time to come, the
removal of environmental agents may be the
simplest solution to this problem. The frequency of
malformations appears to be about doubled, and
the frequency ofcleft lip is increased about 20-fold
inthe offspring ofmothers beingtreated for chronic
seizure disorders with diphenylhydantoin or tri-
methadione (17, 18). Is this an effect ofthe drug or
is itpossible thatthese womenhave a genotypethat
predisposes to both seizure disorder and clefts?
The use of amniocentesis to detect genetic dis-
ease or neural tube closure defects in high risk
populations is assuming an important role, and
there is an increasing amount of practical genetic
information which should and is being given to
parents who wish to participate actively in precon-
ceptual or prenatal planning for their offspring.
Another example of the importance of identify-
ing genotypes may be made by workers in the field
of pharmacogenetics. Certainly there must exist
particular groups of women who because of
molecular changes in detoxifying enzymes are more
vulnerable to teratogenic action of certain drugs.
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genital defect syndromes is of clear importance if
we are to detect teratogenic agents. An example of
this is the association of maternal anticoagulant
therapy (warfarin) with a rare dyschondroplasia,
Conradi Syndrome (19). Another good example is
the identification byJonesetal. (20) ofa recogniza-
ble fetal alcohol syndrome.
Data Storage and Retrieval
As indicated by Dr. Sune Larsson, between 1957
and 1972 there has been a doubling ofthe number
ofscientific articles on developmental subjects with
about 250,000 appearing in 1972. The description
of new dysmorphology syndromes in the human is
creating a staggering task in the efficient applica-
tion of science to medical care. There is a need for
certain types of texts which can be produced from
computer tape print-outs making the material
available to a computer user. Examples of such
books are McKusick's Catalog of Mendelian In-
heritance in Man (21) and.Shepard's Catalog of
Teratogenic Agents (1). These books have the ad-
vantage of rapid, easy revision and cheap produc-
tion.
Other data bank systems exist invarious govern-
ment and corporation offices, but many ofthe data
banks cannot be combined due to technical and/or
political problems. An important element for the
integrated use of these data banks is a universal
identifier system with each chemical compound
being assigned a separate number, such as the
Chemical Abstract Service (CAS) number. The
political problems are in part associated with the
job insecurity created by one computer system can-
nibalizing another. An answer to this is to create a
symbiotic system (umbilical cord) which allows
both merging systems to draw on each other's data.
Such a system isplanned under thetitle ofInterna-
tional Registry ofPotential Toxic Chemicals, spon-
sored by the United Nations Environmental
Programme (UNEP). In the case of teratology,
there is some possibility that a large amount of
useful information, especially on positive findings,
is buried and unpublished in the files of the
pharmaceutical industry. Steps should be taken on
an international basis to foster the collection of
these data through the agency ofexisting organiza-
tions such as the Teratology Information Center
(TIC) in Stockholm. Perhaps ifthe pharmaceutical
companies were to list with TIC their storage of
data oncertain compounds, theproblem oftransfer
oflarge amounts ofinformation could be obviated.
At the same time, this would leave the release on
request of the information up to the individual
pharmaceutical industry. Scientists in the phar-
maceutical industry are knownto beresponsible in-
vestigators, and we believe they should be en-
couraged in every way to contribute to the general
task of teratogen detection.
Rmv iommiandatins
Some recommendations of a group of partici-
pants of this conference are as follows.
1. Recognize the limitations of the present
defenses against teratogenic agents.
2. Educate the public (and medical profession)
about the known human teratogenic agents (Table
1).
3. Select for animal teratogenicity screening
among the vast number of new and existing agents
by emphasizing: substances to which the entire
population will be exposed, agents to which a preg-
nant woman is exposed, viruses which are found to
persist in the human fetus, and agents which
become suspect from clinical observations.
4. Recognize that nearly all compounds have a
fetotoxic dose but this does not imply that they are
teratogenic.
5. Encourage the development of new quick in
vitro testing methods for detecting teratogenic
agents and especially for determining the mechan-
ism of action of those that are known.
6. Monitor for sudden increases inthe frequency
ofspecificmalformations in newborn infants and in
aborted fetuses. Where suspected teratogens are
reported assure that there are expert
multidisciplined committees to evaluatethe threat.
7. Improve our teratology information storage
and retrieval systems by: record linkage of clinical
data, linkage between computer systems, universal
identifier system for chemical compounds and con-
genital malformations, and fostering exchange of
data,particularlythoseheldbythepharmaceutical
industry.
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